Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, & Dr. Ana Garrido-Castro - Evolving ADCs in 1L mTNBC

The first-line treatment landscape for metastatic triple-negative breast cancer is changing rapidly.Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, and Dr. Ana Garrido-Castro discuss how ADCs are reshaping frontline TNBC care and what the latest clinical evidence means for real-world practice.The conversation explores:• The evolution of metastatic TNBC treatment• Why many patients never reach second-line therapy• The impact of ASCENT and sacituzumab govitecan• ASCENT-03 and ASCENT-04 trial results• TROPION-Breast02 and datopotamab deruxtecan• The role of crossover in interpreting overall survival• PFS, OS, and PFS2 as clinical trial endpoints• Selecting between SG and Dato-DXd• Managing neutropenia, stomatitis, ocular toxicity, and ILD• Shared decision-making in frontline TNBC• Why using the best therapy first may matter mostThis comprehensive discussion examines the evidence driving ADC use in metastatic TNBC and how clinicians can individualize treatment selection in an increasingly complex therapeutic landscape.Watch now to hear how ADCs are reshaping frontline TNBC care.